By Lisa Kerner
Charlotte, N.C., Oct. 12 - Amyris Biotechnologies, Inc. said it raised $20 million in a first round of series A venture funding.
The financing was led by Khosla Ventures, with additional participation from Kleiner Perkins Caufield & Byers (KPCB) and Texas Pacific Group Ventures (TPGV).
Samir Kaul, general partner, Khosla Ventures; John Doerr, general partner, KPCB; and Geoff Duyk, managing director, TPGV, joined Amyris' board of directors.
"These new resources will enable the company to expand its capabilities to address major global health and energy challenges, thereby helping to fulfill the promise of synthetic biology," Amyris founder and scientific advisory board member Jay D. Keasling said in a company news release.
"In addition to its ongoing focus on creating a low-cost malaria drug, Amyris will add a new program aimed at renewably producing second-generation, high-performance biofuels with increased cost-effectiveness."
Amyris is a privately held biotechnology company based in Emeryville, Calif.
| Issuer: | Amyris Biotechnologies, Inc.
|
| Issue: | Series A venture funding
|
| Amount: | $20 million
|
| Investors: | Khosla Ventures (lead), Kleiner Perkins Caufield & Byers, Texas Pacific Group Ventures
|
| Announcement date: | Oct. 12
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
